Increasing the dose intensity of chemotherapy by means of granulocyte- colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer (SCLC)

European Journal of Cancer Part A

Volumn 32, Issue 7, 1996, Pages 1263-

  Girling, D J ^a   Thatcher, N ^b   Clark, P I ^c   Stephens, R J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

CANCER CHEMOTHERAPY; DOSE CALCULATION; DOSE RESPONSE; HUMAN; LETTER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 0030176366     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00071-8     Document Type: Letter

References (7)

1. 1. Gridelli C, Perrone F, D'Aprile M, et al. Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer. Eur J Cancer 1995, 31A, 2424-2426.
2. 2. Thatcher N, Anderson H, Bleehen NM, et al. on behalf of the Medical Research Council Lung Cancer Working Party. The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Eur J Cancer 1995, 31A, 152-156.
3. 3. Thatcher N, Clark PI, Smith DB, et al. on behalf of the Medical Research Council Lung Cancer Working Party. Increasing the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Clin Oncol 1995, 7, 293-297.
4. 4. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer: a report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990, 61, 597-604.
5. 5. Sculier JP, Paesmans M, Bureau G, et al. Multiple drug weekly chemotherapy versus standard combination regimen in small cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993, 11, 1858-1865.
6. 6. Souhami RL, Rudd R, Ruiz de Elvira MC, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994, 12, 1806-1813.
7. 7. Souhami RL, Ruiz de Elvira MC. Chemotherapy dose intensity in small cell lung cancer. Lung Cancer 1994, 10 (Suppl. 1), S175-S185.